University of Birmingham Endowment

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, founded in 2011. The company has developed a diagnostic platform that utilizes linear dichroism (LD) technology for a variety of applications, including the detection of antibiotic resistance in infections and testing for bacteria that cause food spoilage. This innovative platform enables simultaneous measurement of multiple targets in a single sample, employing various molecular recognition methods. Additionally, Linear Diagnostics offers a handheld reader specifically designed to measure LD signals. The technology provides significant advantages over conventional methods, facilitating rapid point-of-care tests for infectious diseases and addressing challenges related to antibiotic resistance while aiming to reduce healthcare costs.

Tyseley Energy Park develops an Energy Innovation Zone (EIZ) to help Tyseley and Birmingham overcome the severe energy business and social challenges it currently faces. The TEP EIZ reduces emissions and stimulates growth and will integrate low carbon technologies and infrastructure needed to support new approaches to clean energy.

Smart Antenna Technologies Ltd specializes in designing and developing advanced smart antenna systems for the mobile device and infrastructure markets. The company offers innovative, multi-band, multi-functional, and multi-port antenna solutions that cater to a range of applications including smartphones, laptops, tablets, small cells, Internet of Things devices, and automotive systems. Founded in 2013 as a spinout from the University of Birmingham, Smart Antenna Technologies has patented a pioneering technology that significantly reduces the number of antennas needed in devices, replacing multiple existing antennas with a single, compact unit. This technology not only decreases manufacturing costs and the physical size of devices but also enhances performance and battery life. The company serves a diverse clientele, including handset manufacturers across the United States, Europe, South Korea, Japan, and China, addressing the increasing demand for efficient antenna solutions suitable for next-generation cellular technologies like 4G LTE. With its headquarters in Birmingham and an additional office in Bath, the company continues to drive innovation in antenna design.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.